FY2025 · ended Dec 31, 2025 · Revenue $10.84M, +108340.0% YoY · Filed Feb 26, 2026
Crescent Biopharma, Inc. (CBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $10.8 million and a net loss of $153.9 million. Free cash flow was -$72.5 million. As of Jun 30, 2026 it held $171.6 million in cash and investments and $1.4 million in total debt.
Revenue
$10.84M
+108340.0% vs prior year
Net income (TTM)
$-165.12M
Operating cash flow (TTM)
$-72.68M
-86.6% vs year-ago TTM
Free cash flow (TTM)
$-73.62M
-88.3% vs year-ago TTM
EPS
$-0.59
-1.7% vs prior year
Dividend per share
None
Shares outstanding
27.56M
-57.3% vs prior year
Net cash
$170.16M
as of Jun 30, 2026
Operating margin
-1407.5%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1253689
- Former names
- GLYCOMIMETICS INC (until Jun 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $10.8M | — | $10,000 | $75,000 | $1.2M |
| Operating income | -$152.6M | -$40.0M | -$39.3M | -$47.4M | -$63.4M |
| Net income | -$153.9M | -$37.9M | -$36.9M | -$46.7M | -$63.4M |
| Diluted EPS | — | -$0.59 | -$0.58 | -$0.89 | -$1.23 |
| Operating cash flow | -$71.5M | -$31.1M | -$34.9M | -$46.5M | -$57.5M |
| Free cash flow | -$72.5M | -$31.1M | -$34.9M | -$46.5M | -$57.5M |
| Total assets | $240.3M | $35.6M | $45.3M | $51.8M | $94.3M |
| Total liabilities | $37.3M | $47.1M | $6.9M | $8.9M | $12.7M |
| Stockholders' equity | $203.0M | -$15.5M | $38.4M | $42.9M | $81.6M |
| Cash and investments | $213.2M | $34.8M | $41.8M | $47.9M | $90.3M |
| Total debt | $1.6M | $66,844 | $808,402 | $918,555 | $1.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 14, 2026 | Jul 14, 2026 |
| 10-Q/A | Amended quarterly report | Jun 22, 2026 | Mar 31, 2026 |
All 676 Crescent Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.